Correction of mitochondrial dysfunction in the complex rehabilitation of COVID-19

Tereshin A.E.

North-Western State Medical University named after I.I. Mechnikov;
St. Petersburg State Medical Institution Nikolaevskaya Hospital

Kiriyanova V.V.

St. Petersburg State Pediatric Medical University

ORCID: 0000-0003-2412-7041

Reshetnik D.A.

St. Petersburg State Medical Institution Nikolaevskaya Hospital

Correction of mitochondrial dysfunction in the complex rehabilitation of COVID-19

Authors:

Tereshin A.E., Kiriyanova V.V., Reshetnik D.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8): 25‑29

DOI: 10.17116/jnevro202112108125

Read: 4507 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Tereshin AE, Kiriyanova VV, Reshetnik DA. Correction of mitochondrial dysfunction in the complex rehabilitation of COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):25‑29. (In Russ.)
https://doi.org/10.17116/jnevro202112108125

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the effectiveness of a course of intravenous administration of cytoflavin in combination with a standard rehabilitation program for post-COVID fatigue syndrome caused by mitochondrial dysfunction.

MATERIAL AND METHODS

The dynamic examination of 45 patients with post-COVID syndrome at the second stage of rehabilitation was carried out. The patients were subdivided into 2 groups comparable in gender and age. The volume of lung damage in patients of both groups was also comparable at range of 25—80%. Twenty-four patients of the control group were treated with the standard post-COVID rehabilitation protocol: pulse magnetic therapy, inhalation therapy, aeroion therapy, infrared laser therapy, course aerobic training, psychotherapy, and standard drug therapy. Twenty-one patients of the main group additionally received intravenous administration of cytoflavin daily for 10 days. The dynamics of the scores on the Rehabilitation Routing Scale, HDRS, the Asthenic Status Scale, and the 6-minute walk test was analyzed.

RESULTS AND CONCLUSION

The additional intravenous administration of cytoflavin at the complex rehabilitation of post-COVID syndrome can significantly improve the therapeutic results: it significantly improves the overall functional state, reduces depression and fatigue level and increases tolerance to physical exertion.

Keywords:

new coronavirus infection

COVID-19

rehabilitation

post-COVID syndrome

post-COVID fatigue

mitochondrial dysfunction

Authors:

Tereshin A.E.

North-Western State Medical University named after I.I. Mechnikov;
St. Petersburg State Medical Institution Nikolaevskaya Hospital

Kiriyanova V.V.

St. Petersburg State Pediatric Medical University

ORCID: 0000-0003-2412-7041

Reshetnik D.A.

St. Petersburg State Medical Institution Nikolaevskaya Hospital

Received:

02.04.2021

Accepted:

24.05.2021

List of references:

Temporary guidelines «Prevention, diagnostika and treatment of new coronavirus infection (COVID-19)» Version 10 (08.02.21). M. 261 p.
Temporary guidelines «Medical rehabilitation tation in case of a new coronavirus infection (COVID-19)» Version 2 (07/31/20). M. 151 p.
Holder K, Reddy PH. The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia. Neuroscientist. 2020 Sep 26. Online ahead of print. https://doi.org/10.1177/1073858420960443
Fernández-Ayala D, Navas P, López-Lluch G. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp Gerontol. 2020 Dec. https://doi.org/10.1016/j.exger.2020.111147
Nunn A, Guy G, Brysch W, et al. SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing. Immun Ageing. 2020;17(1):33. https://doi.org/10.1186/s12979-020-00204-x
Burtscher J, Cappellano G, Omori A, et al. Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. iScience. 2020;23(10):101631. https://doi.org/10.1016/j.isci.2020.101631
Gibellini L, De Biasi S, Paolini A, et al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol Med. 2020;12(12):e13001. https://doi.org/10.15252/emmm.202013001
Shenoy S. Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality. Inflamm Res. 2020;69(11):1077-1085. https://doi.org/10.1007/s00011-020-01389-z
Gatti P, Ilamathi HS, Todkar K, Germain M. Mitochondria Targeted Viral Replication and Survival Strategies-Prospective on SARS-CoV-2. Front Pharmacol. 2020;11:578599. https://doi.org/10.3389/fphar.2020.578599
Gvozdjakova A, Klauco F, Kucharska J, Sumbalova Z. Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19? Bratisl Lek Listy. 2020;121(11):775-778. https://doi.org/10.4149/BLL_2020_126
Wood E, Hall K, Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’? Chronic Dis Transl Med. 2020 Nov 21. Online ahead of print. https://doi.org/10.1016/j.cdtm.2020.11.002
Stefano G, Ptacek R, Ptackova H, et al. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce ‘Brain Fog’ and Results in Behavioral Changes that Favor Viral Survival. Med Sci Monit. 2021;27:e930886. https://doi.org/10.12659/MSM.930886
Ouyang L, Gong J. Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19. Med Hypotheses. 2020;144:110161. https://doi.org/10.1016/j.mehy.2020.110161
Afanasyev VV. Cytoflavin in intensive care. Manual for doctors. St. Petersburg. 2005. (In Russ.).
Bul’on VV, Zarubina IV, Kovalenko AL, et al. Cerebroprotector effect of cytoflavin on a closed craniocerebral trauma model. Experimental and Clinical Pharmacology. 2003;6:46-48. (In Russ.).
Kamchatnov PR. Chronic disorders of the cerebral circulation, the possibilities of metabolic therapy. Posobiye. M. 2008;39. (In Russ.).
Klocheva EG, Alexandrov MV, Fomina EB. The use of Cytoflavin in patients with hypoxic state of the brain of ischemic origin. Herald of the St. Petersburg State Medical Academy named after I.I. Mechnikov. 2002;1-2:24-30. (In Russ.).
Fedin AI, Rumyantseva SA, Kuznetsov OR, et al. Antioxidant and energy-protective therapy of ischemic stroke. A methodological guide. M. 2004. (In Russ.).
Fedin AI, Rumyantseva SA, Piradov MA, et al. The effectiveness of the neurometabolic protector Cytoflavin in brain infarcts. Herald of the St. Petersburg State Medical Academy named after I.I. Mechnikov. 2005;1:13-19. (In Russ.).
Fedin AI, Rumyantseva SA, Piradov MA, et al. Clinical efficacy of Cytoflavin in patients with chronic cerebral ischemia (multicenter placebo-controlled randomized trial. Vrach. 2006;13:52-58. (In Russ.).
Zakharov VV, Voznesenskaya TG. Neuropsychiatric disorders. Diagnostic tests. Pod obshh. red. akad. RAN Yakhno N.N. 5-e izd. M.: MED press-inform; 2016. (In Russ.).

Close metadata